Another company, Renovacor, is looking beyond oncology to cardiology – specifically to dilated cardiomyopathy. Its precision gene replacement therapy targets patients with mutations in the BAG3 gene that causes lower levels of BAG3 in the heart. “We want to boost levels of BAG3 in the heart to address the root cause of this aggressive disease,” Matt Killeen, Ph.D., CSO, told BioSpace.